Evvy Raises $40 Million to Build a Data Platform for Vaginal Health

Evvy has closed an oversubscribed $40 million Series B, a signal that investors see real commercial traction in a category most of the healthcare system has ignored for decades: vaginal health.

The round was led by Catalio Capital Management, with participation from Rethink Impact, Muse Capital, Alumni Ventures, LabCorp Venture Fund and General Catalyst, among others. That roster matters. It blends impact-oriented women's health funds with a strategic lab partner in LabCorp and a generalist heavyweight in General Catalyst, suggesting the thesis extends beyond niche appeal.

Evvy's core product is an at-home vaginal health test, clinician-reviewed and paired with personalized treatment plans. Founded in 2021, the company says it has built the world's largest private clinical-grade dataset on the vaginal microbiome. That dataset has already produced peer-reviewed findings, including the identification of six new bacterial vaginosis subtypes and hundreds of previously uncatalogued vaginal microbiome genomes.

The capital will fund two things: clinical validation of Evvy's AI-powered diagnostic and care models, starting with fertility, and expanded distribution through physician and partner channels. Priyanka Jain, Evvy's co-founder and CEO, framed the mission in blunt terms. "Our interest is in exploring biomarkers in the female body that we've underleveraged, that can help us understand women's health outcomes," she told Fierce Healthcare.

Jain's frustration with the pace of public research funding is a recurring theme in her comments. "I do not want to wait for the government to fund women's health research and especially vagina research," she said. "We have forever defined health and disease based on middle-aged, midsized white men." That line is not rhetorical flourish. It is the investment thesis in a sentence: a data gap this large, in a population this large, represents an addressable market that traditional research infrastructure has left largely uncontested.

Why the Data Moat Matters

Precision medicine businesses live or die on proprietary data, and Evvy's pitch rests heavily on the size and specificity of its dataset. Jacob Vogelstein, co-founder and managing partner at Catalio Capital, put it plainly in the funding announcement: "We were drawn to Evvy not only because of its growth, but because of the unique data and AI infrastructure the company is building, and the exceptional team executing on it." He called the combination of proprietary data, clinical evidence and a growing biomarker discovery engine "an entirely new foundation for precision women's healthcare."

That framing is worth scrutinizing rather than simply repeating. Data moats are only durable if the data keeps compounding and if clinical validation follows. Evvy has a fertility study underway with IVF clinics through US Fertility, sampling patients' vaginal microbiomes to see whether outcomes can be predicted. Results are expected later this year. Until that study and others are published and peer-reviewed, the "new foundation for precision women's healthcare" remains a promising hypothesis rather than an established clinical standard.

The commercial case is more concrete. Evvy has served more than 100,000 patients and 3,000 practitioners to date. Its model is dual-track: direct-to-consumer sales alongside business-to-business partnerships with clinics and platforms such as Carrot and Parsley. Patients can collect a sample at home or in a clinic, and a provider-facing portal lets clinicians order tests, review results and consult with Evvy's clinical team. The one-time test costs $159, with subscription discounts for quarterly testing. Reimbursement is not yet standard. Jain says the company is working on securing insurance coverage, a step that would meaningfully widen the addressable market if achieved.

Context helps explain why investors are willing to write checks into this space now. Vaginal symptoms rank among the leading reasons women seek healthcare in the U.S., according to Harvard Health, yet misdiagnosis rates remain high. Many patients default to over-the-counter self-treatment, often for the wrong condition. That combination of high prevalence and poor diagnostic accuracy is exactly the kind of inefficiency that data-driven diagnostics are designed to exploit. A broader PwC report projects the women's health sector could grow into a $600 billion industry by 2030, a macro tailwind that helps justify valuations across the category, Evvy included.

The company has also layered in an AI product, EvvyAI, launched earlier this year. The rationale is straightforward: patients increasingly turn to chatbots for health answers, but general-purpose AI models reportedly fail on 60% of women's health questions, according to a study cited by the company. Evvy already offered free phone-based health coaching to test-takers, but adoption was uneven. "A lot of patients would still not want to talk to someone live and would want to write in," Jain said. EvvyAI offers a conversational interface with human escalation available when needed.

The Bottom Line

Evvy's $40 million raise is a bet on two converging trends: a long-neglected data gap in women's health and the maturation of AI tools capable of exploiting that gap commercially. The strategic backing of LabCorp Venture Fund adds a credible distribution and lab-science signal, while General Catalyst's involvement suggests generalist investors are willing to underwrite category-defining bets in a historically underfunded niche.

The risks are real. Reimbursement remains unresolved, clinical validation studies are still pending publication, and the company's claim to a durable data moat depends on continued patient growth at scale. Investors watching this space should track whether the US Fertility study delivers statistically meaningful predictive findings, whether insurance payers begin covering the test, and whether EvvyAI's accuracy claims hold up under independent scrutiny. If those milestones land, Evvy's Series B will look like an early, well-priced entry into a genuinely underserved market rather than a wellness brand riding a hot sector.